Sofwave Medical Ltd.

Sofwave Medical Ltd.

3,488.00
ILA
+3.00
(+0.09%)
149.93BMarket Cap
Sofwave Medical Ltd.
TASE:SOFW
(Tel Aviv Stock Exchange)

Recent

price

3,488.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
2025
TTM
USD
- -
0.01
0.13
0.93
1.05
1.47
1.74
2.48
- -
Revenue per Share
- -
-0.1
-0.34
-0.29
-0.57
-0.24
-0.13
0.15
- -
Basic EPS, GAAP
- -
-0.09
-0.15
-0.22
-0.33
-0.2
-0.08
0.36
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
-0.02
0.12
0.04
1.36
0.93
0.77
0.7
0.89
1.05
Book Value per Share
-0.02
0.12
0.04
1.36
0.93
0.77
0.7
0.89
1.05
Tangible Book Value per Share
34
34
34
23
34
34
34
35
36
Basic Weighted Avg Shares
- -
- -
4
22
36
50
60
88
- -
Sales/Revenue/Turnover
- -
-1,137.41
-152.67
-40.6
-48.66
-15.88
-6
7.84
- -
Operating Margin (%)
- -
- -
- -
- -
1
2
2
2
- -
Depreciation Expense
- -
-3
-12
-7
-20
-8
-5
5
- -
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
4.34
- -
Effective Tax Rate (%)
- -
-1,239.21
-272.36
-31.26
-54.81
-16.45
-7.62
6.26
- -
Profit Margin (%)
- -
6
2
45
30
23
21
29
34
Working Capital
- -
- -
- -
2
1
1
1
- -
1
LT Debt
-1
4
2
47
32
26
25
33
38
Total Equity
- -
- -
- -
- -
- -
- -
- -
-22.25
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
18.59
- -
Return on Capital (%)
- -
- -
-413.85
-28.3
-49.41
-28.21
-17.87
19.17
- -
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
37
36
36
Market Capitalization
317
427
506

Working Capital

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
51
53
57
Cash, Cash Equivalents & STI
35
35
28
Accounts Receivable, Net
8
8
10
Inventories
5
5
6
Total Current Liabilities
22
22
23
Payables & Accruals
- -
- -
- -
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
584.72%
33.36%
Free Cash Flow
- -
-112.23%
-577.4%
Net Income, GAAP
- -
-35.78%
-220.7%
Sales/Revenue/Turnover
- -
115.76%
46.92%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
13
15
14
18
60
2025
17
21
- -
29
88
2026
24
30
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.03
-0.04
-0.04
-0.02
-0.13
2025
-0.03
0.04
- -
0.11
0.15
2026
0.03
0.07
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Business
Sofwave Medical Ltd. develops advanced ultrasound technology for aesthetic treatments in both domestic and international markets. The company provides non-invasive medical devices that utilize Synchronous Ultrasound Parallel Beam (SUPERB) technology, enabling physicians to address various skin concerns. These solutions are engineered to improve facial lines and wrinkles, lift lax tissue in areas like the submental and neck regions, enhance the appearance of cellulite, and firm the skin on the upper arms. Established in 2015, Sofwave Medical Ltd. maintains its operational foundation in Yokne'am Illit, Israel, with a significant global presence and headquarters located in California, United States.